Tech Company Financing Transactions
Nohla Therapeutics Funding Round
5AM Ventures, Alexandria Venture Investments and AML Biotech Partners participated in a $45 million Series B venture round for Nohla Therapeutics. The round was announced on 5/16/2018.
Transaction Overview
Company Name
Announced On
5/16/2018
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series B
Investors
Proceeds Purpose
Nohla intends to use the proceeds to complete the ongoing Phase 2 trials of its lead candidate, dilanubicel (NLA101), in allogeneic transplant and chemotherapy-induced myelosuppression, as well as support Phase 3 trial and commercial manufacturing needs. Proceeds will also be used to advance the company's novel cell-based therapy platform and pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1600 Fairview Ave. E. 100
Seattle, WA 98102
USA
Seattle, WA 98102
USA
Phone
Website
Email Address
Overview
Nohla Therapeutics is a company that's redefining clinical outcomes for patients with critical diseases by providing a short-term hematopoietic bridge to immune repair and healthy blood production with long-term immunologic benefits.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Steven Gillis
Chief Executive Officer
Kathleen Fanning
Chief Financial Officer
James Johnson
Chief Medical Officer
Colleen Delaney
Chief Operating Officer
Gary Christianson
Browse more venture capital transactions:
Prev: 5/16/2018: Circle venture capital transaction
Next: 5/16/2018: OrthoSensor venture capital transaction
Share this article
About Our VC Transactions Data
We document every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs